REG - Shield Therapeutics - Total Voting Rights

Shield TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260227:nRSa6149Ua&default-theme=true

RNS Number : 6149U  Shield Therapeutics PLC  27 February 2026

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Total Voting Rights

 

London, UK, 27 February, 2026: Shield Therapeutics plc (LSE: STX), a
commercial-stage pharmaceutical company specialising in iron deficiency
confirms that in accordance with the requirements of the FCA's Disclosure and
Transparency Rule 5.6.1, the Company's issued share capital consists of
1,068,418,471 ordinary shares of 1.5p each in issue, each with equal voting
rights. No shares are held in treasury.

 

The above figure may also be used by shareholders as the denominator in the
calculations by which they will determine whether they are required to notify
their interest, or a change to their interest, in the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500

 Santosh Shanbhag, CFO                                                                          Investorrelations@shieldtx.com

 Stephanie Hicks, Investor Relations

 https://shieldtherapeutics.com/link/PlYOay
 (https://shieldtherapeutics.com/link/PlYOay)

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel                                                                                    +44 (0)20 7418 8900

 Joint Broker

 Cavendish Ltd

 Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet                                                   +44 (0)20 7220 0500
 Ward

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients and is now the leading #1
branded prescription oral iron the market today (data source - IQVIA Xponent
PlanTrak).

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company launched
ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement
with Viatris. Outside of the U.S., the Company has licensed the rights to five
specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and
European Union by Norgine B.V., which also has marketing rights in Australia
and New Zealand. FeRACCRU® is also commercialised in Canada by Kye
Pharmaceuticals Inc. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and
Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with
Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPPUUUPUPQPUQ



            Copyright 2019 Regulatory News Service, all rights reserved